AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00480311 — intervention group
Intervention type: OTHER
Intervention: WHODAS II (World Health Organization Disability Assessment Schedule II)
Description: To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
Study NCT01589120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video decision aid
Description: Video decision aid of the goals of care
Study NCT03493503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Intravenous Salbutamol loading dose
Study NCT03493503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: 10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
Study NCT01970150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS real
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental cycling test (ICT)
Description: Incremental cycling test to volitional exhaustion
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental cycling test (ICT)
Description: Incremental cycling test to volitional exhaustion
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant load cycling test (CET)
Description: Constant load cycling test to volitional exhaustion.
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant load cycling test (CET)
Description: Constant load cycling test to volitional exhaustion.
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental respiratory muscle test (IncRMET)
Description: Incremental respiratory muscle test to volitional exhaustion.
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental respiratory muscle test (IncRMET)
Description: Incremental respiratory muscle test to volitional exhaustion.
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incremental quadriceps muscle test (IncQMT)
Description: Incremental quadriceps muscle test to volitional exhaustion.
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental quadriceps muscle test (IncQMT)
Description: Incremental quadriceps muscle test to volitional exhaustion.
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training like interventions
Description: Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
Study NCT03997838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 1000 mg of VVZ-149
Study NCT03997838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0 mg of VVZ-149
Study NCT04151004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training like interventions
Description: Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
Study NCT02094469 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol
Description: Oral, Bid, 24 weeks
Study NCT02229994 — intervention group
Intervention type: OTHER
Intervention: Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
Description: Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment.
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: energy drink
Description: 16 oz cold commercially-available energy drink
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caffeinated drink
Description: 16oz cold commercially-available caffeinated drink
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy gum
Description: 2 pieces of commercially-available energy gum
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo gum
Description: 2 pieces of commercially-available placebo gum
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gum
Description: 2 pieces of commercially-available placebo gum
Study NCT01768260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced external counterpulsation
Description: EECP is performed for 1 hours every day, for a total of 36 hours.
Study NCT01768260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Standard drug therapy
Study NCT01296841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collaborative Imaging
Description: Hardware and software communication tools to provide clinical care from a distance.
Study NCT00758797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoimmunotherapy
Description: DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control drink
Description: 16oz cold control drink
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: 16oz cold control drink
Study NCT03324256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total sleep deprivation
Description: 24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
Study NCT04778072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 25mg twice daily
Description: ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
Study NCT03336840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin tablets
Description: 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
Study NCT03336840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProMetS probiotics powder
Description: 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study NCT03336840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Metformin tablets; 2. ProMetS probiotics powder
Description: 1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study NCT04471740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSF shunt diversion
Description: Clinical response to a CSF shunt insertion
Study NCT04471740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF shunt diversion
Description: Clinical response to a CSF shunt insertion
Study NCT02601781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PPCI)
Description: Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
Study NCT02601781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS ABSORB)
Description: BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
Study NCT01070303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg eow or ew
Description: Adalimumab 40 mg by subcutaneous injection every other week or every week
Study NCT05743543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block
Description: The block is performed with a nasoscope and the administration of a local anesthetic.
Study NCT02502630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
Study NCT02234115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Mesylate
Description: Subcutaneous injection of 50mg Leuprolide Mesylate
Study NCT03131297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment by radiofrequency
Description: Radiofrequency might destroy fistula tract without lesion of anal sphincter.
Study NCT03516799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
Study NCT01834326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVPOME (autogenous ex vivo produced oral mucosa equivalent)
Description: EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
Study NCT01834326 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: POM (Palatal oral mucosa)
Description: POM is a tissue graft harvested from the palate and surgically placed into the defect area
Study NCT01478087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mysorba
Description: Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
Study NCT03941262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells
Study NCT03941262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
Study NCT03941262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
Study NCT03073304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid based prime solution
Description: Crystalloid based prime solution
Study NCT03073304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocyte based prime solution
Description: Erythrocyte based prime solution
Study NCT02636036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enadenotucirev
Study NCT02636036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Study NCT00666575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
Study NCT00666575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
Study NCT02719366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A Extended Range test lens
Description: contact lenses
Study NCT02719366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A Extended Range test lens
Description: contact lenses
Study NCT02719366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A control lens
Description: contact lenses
Study NCT02719366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A control lens
Description: contact lenses
Study NCT02226783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 salt tablet
Description: AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
Study NCT02226783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 free base tablet
Description: AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
Study NCT02226783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 free base tablet + Omeprazole
Description: AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
Study NCT02923622 — intervention group
Intervention type: OTHER
Intervention: Traditional Chinese medicine herbals
Description: TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
Study NCT02923622 — intervention group
Intervention type: OTHER
Intervention: Integrated traditional Chinese and Western medicine
Description: TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
Study NCT02923622 — intervention group
Intervention type: OTHER
Intervention: Western medicine
Description: Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin 1000 mg bid. for 14 days
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: clarithromycin 500 mg bid. for 14 days.
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinidazole
Description: tinidazole 500 mg bid. for 14 days.
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: levofloxacin 500 mg qd. for 14 days.
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furazolidone
Description: furazolidone 100 mg bid. for 14 days.
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline
Description: tetracycline 750 mg bid. for 14 days.
Study NCT03139253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 5 mg bid. for 14 days.
Study NCT02864914 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: drug
Study NCT02864914 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: drug
Study NCT01340170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed TX
Description: OsseoSpeed TX dental implants, 6-17 mm
Study NCT01340170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsseoSpeed TX
Description: OsseoSpeed TX dental implants, 6-17 mm
Study NCT01356888 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)
Description: Stenting
Study NCT01356888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (Orsiro DES)
Description: stenting
Study NCT04296682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Preservation With Gingival Graft
Description: Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
Study NCT04595578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar repetitive transcranial magnetic stimulation
Description: rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
Study NCT04595578 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cerebellar repetitive transcranial magnetic stimulation
Description: rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
Study NCT02313454 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intranasal Tear Neurostimulator
Description: Neurostimulation applied intranasally and extranasally.
Study NCT02004340 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ear vagus nerve stimulator
Study NCT02004340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ear vagus nerve stimulator
Study NCT02984878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra
Description: Nasolabial Fold correction
Study NCT06094712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: CORT125134 150-mg capsule
Study NCT04729530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dyson Pure Cool - Active Purifier
Description: Free standing air purifier
Study NCT04729530 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dyson Pure Cool - Placebo purifier
Description: Placebo air purifier
Study NCT02542449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Globes®
Description: At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
Study NCT02542449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
Study NCT02313454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator
Description: Neurostimulation applied intranasally and extranasally.
Study NCT02551250 — intervention group
Intervention type: DEVICE
Intervention: annual noncontrast MRI
Description: liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
Study NCT02551250 — intervention group
Intervention type: DEVICE
Intervention: biannual ultrasonography
Description: liver ultrasonography for HCC screening performed by experienced sonologists
Study NCT04325399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Study NCT01578720 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EYLEA (Aflibercept) intravitreal injection
Description: Intravitreal Injection once every 8 weeks with 3 initial monthly doses
Study NCT04720833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dried plum
Description: Dried plum
Study NCT04720833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and vitamin D
Description: Calcium and vitamin D supplement
Study NCT01742052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Low
Study NCT01742052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Middle
Study NCT01742052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-High
Study NCT01742052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02191397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
Study NCT02191397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Matching Placebo
Description: Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
Study NCT02191397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
Study NCT02191397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Matching Placebo
Description: Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding